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Abstract
Background Surgery is the fundamental curative option
for gastric cancer patients. Imaging scans are routinely
prescribed in an attempt to stage the disease prior to sur-
gery. Consequently, the correlation between radiology
exams and pathology is crucial for appropriate treatment
planning.
Methods Systematic searches were conducted using
Medline, Embase, and the Cochrane Central Register of
Controlled Trials from January 1, 1998 to December 1,
2009. We calculated the accuracy, overstaging rate, un-
derstaging rate, Kappa statistic, sensitivity, and specificity
for abdominal ultrasound (AUS), computed tomography
(CT), magnetic resonance imaging (MRI), and positron
emission tomography (PET) with respect to the gold
standard (pathology). We also compared the performance
of CT by detector number and image type. A meta-analysis
was performed.
Results For pre-operative T staging MRI scans had better
performance accuracy than CT and AUS; CT scanners
using C4 detectors and multi-planar reformatted (MPR)
images had higher staging performances than scanners with
\4 detectors and axial images only. For pre-operative N
staging PET had the lowest sensitivity, but the highest
specificity among modalities; CT performance did not
significantly differ by detector number or addition of MPR
images. For pre-operative M staging performance did not
significantly differ by modality, detector number, or MPR
images.
Conclusions The agreement between pre-operative TNM
staging by imaging scans and post-operative staging by
pathology is not perfect and may affect treatment deci-
sions. Operator dependence and heterogeneity of data may
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account for the variations in staging performance. Physi-
cians should consider this discrepancy when creating their
treatment plans.
Keywords Abdominal ultrasound (AUS)  Computed
tomography (CT)  Magnetic resonance imaging (MRI) 
Positron emission tomography (PET)  Gastric cancer
Introduction
Currently, resection is the only curative option available
for patients with gastric cancer [1–4]. Accurate assessment
of local tumor depth invasion (T), regional lymph node
invasion (N), and distant metastases (M) is crucial to
appropriate surgical and treatment planning [1, 2, 5]. Un-
derstaging of the disease may lead to positive resection
margins or unnecessary laparotomy if metastases were not
identified on pre-operative imaging. Overstaging a patient
may lead to ineffective care if a potentially curative patient
is incorrectly categorized as a palliative patient [5].
Available pre-operative staging modalities include
abdominal ultrasound (AUS), computed tomography (CT),
magnetic resonance imaging (MRI), and positron emission
tomography (PET). Current National Comprehensive
Cancer Network (NCCN) practice guidelines for gastric
cancer [6] suggest using a variety of techniques as part of
the workup, including CT of abdomen and pelvis, chest
imaging, pelvic ultrasound, PET, PET-CT, esophagogas-
troduodenoscopy (EGD), and endoscopic ultrasound
(EUS). However, the guidelines do not recommend specific
modalities or workup pathways [6].
Despite the routine use of the above imaging modalities
for pre-operative staging, each modality has limitations.
AUS has difficulty in evaluating the wall of the gastric
fundus and greater curvature, as well as lymphatic spread
[7, 8]. It is also highly dependent on patient body habitus
and the operator [9]. Traditional single detector scanners
(S-CT) are limited by large section thickness, low image
resolution, and slow scanning causing respiratory motion
artifacts, and they are unable to provide multi-planar ref-
ormations [10, 11]. Multi-detector row CTs (MDCTs) have
difficulty in detecting flat type lesions and have poor soft
tissue contrast resolution [10, 11]. Nodal assessment is
limited to size criteria, which does not allow diagnosis of
microscopic nodal invasion or the exclusion of enlarged
reactive nodes [10]. MRI scans have limitations including
respiratory motion artifacts, long examination time, high
costs, and lack of a standard gastric protocol [12, 13].
Assessment of nodal status by MRI is also limited to size
criteria. Furthermore, MRI is limited in the amount of body
coverage that can be achieved in a single exam, making it
unsuitable for M staging [14]. 18-F-Fluoro-2-deoxyglucose
positron emission tomography (FDG-PET, simplified as
PET throughout this paper) uses a semi-quantitative
method, the standardized uptake value (SUV), to assess the
uptake of FDG in a tumor [15]. However, SUVs are
dependent on several factors, including time post FDG
injection, tumor size, normoglycemia, and technical
parameters [16, 17]. PET is also highly dependent upon the
pathological subtype of the cancer, as mucinous tumors
may give false-negative results [15].
The limitations of each technique have an effect on the
ability of these modalities to accurately stage gastric cancer
prior to surgery [1–4, 7, 8, 10–13, 15–17], yet patient
operability and tumor resectability are heavily dependent
on the quality of pre-operative imaging [5]. Therefore, the
purpose of this review is to provide a detailed meta-anal-
ysis of the pre-operative TNM staging abilities of AUS,
CT, MRI, and PET in patients with pathology-confirmed
gastric cancer over the past decade.
Methods
Data sources
Electronic literature searches were conducted using Med-
line and Embase from January 1, 1998 to December 1,
2009, according to the search algorithm presented in
Appendix A of electronic supplementary material. Search
terms included: [exp stomach cancer/or (((gastric or
stomach) adj1 cancer$) or ((gastric or stomach) adj1 car-
cinoma) or ((gastric or stomach) adj1 adenocarcinoma) or
((gastric or stomach) adj1 neoplasm$)).mp.] and [cancer
staging/or diagnostic imaging/or exp computer assisted
tomography/or computer assisted emission tomography/or
exp positron emission tomography/or exp nuclear magnetic
resonance imaging/or exp barium meal/] and [clinical trial/
or controlled clinical trial/or exp comparative study/or
meta analysis/or multicenter study/or exp practice guide-
line/or randomized controlled trial/] not [review or case
report/] not [*gastrointestinal stromal tumor/or exp B cell
lymphoma/and ‘‘marginal zone’’.mp.]. A separate search of
the Cochrane Central Register of Controlled Trials
(1998–2009) was performed using the search term ‘‘gastric
cancer’’. Reference lists from review papers and relevant
articles were also examined for additional studies that met
our inclusion criteria.
Study selection and review process
To be eligible, studies had to meet the following criteria:
(1) investigation of preoperative T, N, or M staging per-
formance of AUS, CT, MRI, or PET in newly (not recur-
rent) diagnosed patients with histopathology-confirmed
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gastric adenocarcinoma; (2) patients underwent surgery,
and pre-operative staging was compared with post-opera-
tive pathological staging; (3) studies involved human
patients with a minimum of 30 patients; and (4) studies
were published in peer reviewed journals in English.
Studies were excluded according to the following exclu-
sion criteria: (1) studies that involved animals and/or ex
vivo samples; (2) studies that involved patients with mixed
cancer or studies investigating the diagnostic performance
in other cancers with no separate analysis of gastric cancer
subjects; (3) studies that did not provide sufficient infor-
mation to determine pre-operative T, N, or M staging
performance; and (4) review articles, meta-analyses,
abstracts, conference proceedings, editorials/letters, and
case reports. Studies that reported performance character-
istics on more than one imaging technique were included
only if the images from each technique were independently
analyzed and the reviewers were blinded. All electronic
search titles, selected abstracts, and full-text articles were
independently reviewed by a minimum of two reviewers
(NC, LP, AM, RC, RS). Disagreements on study inclusion/
exclusion were resolved with a consensus meeting.
Data extraction
A systematic approach to data extraction was used to
produce a descriptive summary of participants, interven-
tions, and study findings. The first reviewer (RS) inde-
pendently extracted the data and a second reviewer (RC,
CM) checked the data extraction. No attempt was made to
contact authors for additional information. The TNM
staging categories were extracted from corresponding
publications. Staging classifications for individual studies
can be found in Appendices 1–4 of the electronic supple-
mentary material. Modality-specific staging definitions
incorporated by the majority of studies are shown in Fig. 1.
Both the Union International Contre le Cancer (UICC)/
American Joint Committee on Cancer (AJCC) staging
T Stage AUS Criteriaa
T0 No evidence of alteration to any of the 5 gastric layers 
T1 Layers 1 to 3 are interrupted or thickened while the 4th and 5th layers are normal 
sonographically
T2 4th layer is thickened while the 5th layer is intact sonographically 
T3 Interruption or disappearance of all 5 layers of the gastric wall sonographically 
T4 Tumor invading adjacent organs: has an indistinct border and is indistinguishable from involved organs sonographically 
N Stage AUS Criteriaa
N0 No evidence of lymph node metastasis 
N1 Metastasis in the perigastric node(s) closer than 3 cm to the primary lesion 
N2 Metastasis in the perigastric node(s) distance of more than 3 cm to the primary lesion 
N3 Metastasis in hepatoduodenal, peripancreatic, superior mesenteric, paraaortic, 
and middle colic nodes 
M Stage AUS Criteriaa
M0 Distant metastasis absent 
M1 Distant metastasis present 
T Stage MRI Criteriac
T0 No detectable primary lesion at the stomach wall 
T1 Enhancing tumor does not penetrate the enhancing submucosal layer 
T2 Clear continuous low signal intensity band or enhancing cancerous portion do not penetrate the low signal intensity band 
T3 Interrupted low signal intensity band or enhancing cancerous portion penetrates the 
outer low signal intensity band 
T4 Continuous extension of the cancerous portion to the adjacent organ 
with or without interruption of low signal intensity band 
N Stage MRI Criteriac
N0 No evidence of lymph node metastasis 
N1 Metastasis in the perigastric node(s) closer than 3 cm to the primary lesion 
N2 Metastasis in the perigastric node(s) distance of more than 3 cm to the primary lesion 
N3 Metastasis in hepatoduodenal, peripancreatic, superior mesenteric, paraaortic, and 
middle colic nodes 
M Stage MRI Criteriac
M0 Distant metastasis absent 
M1 Distant metastasis present 
T Stage PET Criteriad
T0 No increase in 18F-FDG uptake within the stomach 
T+  Increased 18F-FDG uptake exceeding that of the adjacent normal gastric wall 
N Stage PET Criteria (described by the JGCA)d
N0 No evidence of lymph node metastasis 
N1 Increased 18F-FDG uptake in the perigastric nodes 
N2 Increased 18F-FDG uptake in the nodes along the celiac artery and its branches 
N3 Increased 18F-FDG uptake in the retropancreatic or paraortic nodes 
N stage PET Criteria (described by AJCC/UICC)d
N0 No regional lymph node metastases 
N1 Increased 18F-FDG uptake in 1-6 regional lymph nodes 
N2 Increased 18F-FDG uptake in 7-15 regional lymph nodes 
N3 Increased 18F-FDG uptake in > 15 regional lymph nodes 
M Stage PET Criteriad
M0 Distant metastases absent 
M1 Increased 18F-FDG uptake in distant metastases 
T Stage CT Criteriab
T0 No evidence of alteration of the gastric wall with normal fat plane 
T1 
Neoplasm shows focal thickening of inner layer, is almost well enhanced, and has 
visible low-attenuation-strip outer layer of gastric wall and clear fat plane around 
tumor
T2 
Neoplasm shows focal or diffuse thickening of gastric wall with transmural 
involvement, is almost well enhanced, and has smooth outer wall border and clear 
fat plane around tumor 
T3 Transmural tumor with irregular or nodular outer border and/or perigastric fat infiltration 
T4 Obliteration of fat plane between gastric tumor and adjacent organ or invasion of 
adjacent organ 
N Stage CT Criteria (described by the JGCA)b
N0 No evidence of lymph node metastasis 
N1 metastasis in the perigastric nodes 
N2 metastasis in the nodes along the celiac artery and its branches 
N3 metastasis in the retropancreatic or para-aortic nodes 
N stage CT Criteria (described by AJCC/UICC)b
N0 No regional lymph node metastases 
N1 Metastases in 1-6 regional lymph nodes 
N2 Metastases in 7-15 regional lymph nodes 
N3 Metastases in > 15 regional lymph nodes 
M Stage CT Criteria 
M0 Distant metastasis absent 
M1 Distant metastasis present 
Fig. 1 TNM staging criteria for gastric cancer by modality. aAdapted
from [42, 43]. bAdapted from [28, 53]. cAdapted from [36].
dAdapted from [50, 56]. All articles adapted the above definitions or
slight variations of these definitions when describing their respective
modalities. AUS, abdominal ultrasound; CT, computed tomography;
JGCA, Japanese Gastric Cancer Association; AJCC, American Joint
Committee on Cancer; UICC, Union International Contre le Cancer;
MRI, magnetic resonance imaging; PET, positron emission
tomography
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classifications [18], and the Japanese Gastric Cancer
Association (JGCA) 2nd English edition [19] classification
system were used (Appendix B of the electronic supple-
mentary material).
Data analysis
A range of definitions was found for the calculation of
accuracy, sensitivity, and specificity. Therefore, the fol-
lowing performance characteristics were re-calculated from
the original numbers provided in each included publication:
detection rate, accuracy, overstaging rate, understaging rate,
agreement/kappa statistic (j), sensitivity, and specificity.
Detection rate was defined as the ability to detect the pres-
ence of a tumor. Accuracy was defined as the ability to match
the pre-operative stage of a given tumor with the post-
operative pathology staging (i.e., T1 accuracy = [number
correctly staged by pre-operative imaging technique as
T1/number staged by pathology as T1] 9 100). Over- and
understaging refer to when the tumor was incorrectly staged
higher and lower compared to post-operative pathological
staging, respectively. Overall calculations for accuracy,
overstaging rate, and understaging rate were based on the
average performance values for all cases (i.e., combined
values for T1–T4; i.e., overall accuracy = [number of cases
correctly staged/number of all cases] 9 100). Agreement
between the pre-operative imaging technique and pathology
was calculated using a 4 9 4 table (corresponding to stages
T1, T2, T3, and T4). A 5 9 5 table was used when the pre-
operative imaging technique did not detect the presence of a
tumor (stage T0), while a 3 9 3 table was used when two of
the stages were combined (e.g., T1–T2). The following
interpretation of j was used:\0 = less than chance agree-
ment; 0.01–0.20 = slight agreement; 0.21–0.40 = fair
agreement; 0.41–0.60 = moderate agreement; 0.61–0.80 =
substantial agreement; 0.81–0.99 = almost perfect agree-
ment [20]. For pre-operative N staging, sensitivity and
specificity of staging a lymph node as negative (N0) or
positive (N?) was determined using a 2 9 2 table (corre-
sponding to N0 and N?). For pre-operative M staging,
sensitivity and specificity of staging metastases as negative
(M0) or positive (M1) was determined using a 2 9 2 table
(corresponding to M0 and M1). Overall calculations for
sensitivity and specificity for N and M stage were based on
the average values for all cases (i.e., N0–N? and M0–M?).
Statistical analyses were conducted using R version 2.10.1
statistical package (http://cran.r-project.org/). Meta-analysis
(pooling of data) was calculated using the inverse variance
method and the random effects estimate based on the
DerSimonian–Laird method [21]. Only performance char-
acteristics that were re-calculated were included in pooling
analyses. Significance within and between imaging
techniques was calculated by comparing pooled scores.
A Bonferroni correction was applied when multiple com-
parisons were made such that significance was reached when
P B a/N (where a = 0.05 and N = number of comparisons/
outcomes measured) [22].
Results
Literature search
A total of 5204 titles/abstracts were identified from the
electronic searches and reference lists for preliminary
review. After removal of duplicates and screening for rel-
evant titles and abstracts, a total of 167 articles were sub-
mitted for a full-text review. A total of 40 articles [23–62]
involving 3758 patients met our inclusion criteria and were
included in this review (Fig. 2). We included 29 prospec-
tive studies and 11 retrospective studies.
Performance characteristics of pre-operative imaging
studies
Overall TNM staging results for each technique (AUS, CT,
MRI, and PET) are presented in Tables 1, 2, 3, and 4,
respectively, with more detailed (stage/metastatic site
specific) analyses found in the correspondingly numbered
electronic Appendices 1–4 of the electronic supplementary
material. For the evaluation of pre-operative diagnostic
AUS (3 studies [37, 42, 43]), a total of 168 patients were
assessed for T stage, 149 patients were assessed for N
stage, and 101 patients were assessed for M stage pre-
operatively by AUS and post-operatively by pathology. For
the evaluation of pre-operative diagnostic CT (32 studies
[23–35, 37–42, 44–49, 52–59]), a total of 2909 patients
were assessed for T stage, 2646 patients were assessed for
Articles identified from search = 5204 
Articles excluded based on title and abstract = 5014 
Articles selected for full text review = 167 
Articles excluded = 127 
• Irrelevant Topic/Analysis (not diagnostic 
accuracy, no pathology comparison, non TNM 
staged, recurrent patients, pre-op chemo) = 88 
• Guideline/Review = 18 
• N < 30 patients = 12 
• Mixed cancer/combined analysis = 9 
Articles included in this systematic review = 40 
Fig. 2 Article selection flow
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N stage, and 916 patients were assessed for M stage pre-
operatively by CT and post-operatively by pathology. For
the evaluation of pre-operative diagnostic MRI (3 studies
[36, 49, 51]), a total of 109 patients were assessed for T
stage, and 75 patients were assessed for N stage pre-
operatively by MRI and post-operatively by pathology. For
the evaluation of pre-operative diagnostic PET (9 studies
[29, 44, 45, 50, 55, 56, 60–62]), a total of 422 patients were
assessed for T stage, 420 patients were assessed for N
stage, and 282 patients were assessed for M stage pre-
operatively by PET and post-operatively by pathology.
Comparison of AUS, CT, MRI, and PET
The pooled TNM performance characteristics of all
modalities are reported in Table 5. Overall, MRI had sig-
nificantly better T staging performance compared to all CT
scanners, as well as better T1 staging performance com-
pared to AUS. Because PET cannot stage cancers by tumor
depth, we calculated the primary tumor detection rate
reported in all studies. This pooled value was 80.4 ± 4.9%,
with an overall detection rate ranging from 58.1 to 95.9%
(Appendix 4.3 of the electronic supplementary material).
The primary tumor detection rates for AUS, CT, and MRI
ranged from 90.7–100, 61.1–100, and 97.8–100%, respec-
tively (Appendices 1.3, 2.3, and 3.3 of the electronic sup-
plementary material). For N staging, PET had the lowest
sensitivity and the highest specificity. There was no supe-
rior modality for determining M stage.
Pre-operative TNM staging performance by detector
number and use of multi-planar images
We compared the pooled TNM performance characteristics
of CT scanners with \4 detectors [25, 26, 30–33, 35, 37,
40–42, 46, 49, 52, 57, 59] to those with C4 detectors [23,
24, 27, 28, 34, 38, 39, 47, 48, 53–55, 58], to determine
whether the use of more detector rows to capture images
translated into better pre-operative staging performances
(Table 6). Overall, CT scanners with C4 detectors had
significantly better T staging performances compared to
CT scanners with\4 detectors. However, detector number
did not significantly affect N or M staging performances.
We compared the pooled TNM performance character-
istics of CT scanners using traditional single plane axial
images [25, 28–35, 37, 38, 40–42, 46, 49, 52, 57–59] with
scanners using multi-planar reformatted (MPR) images
[23, 24, 27, 28, 34, 38, 39, 44, 47, 48, 53–56, 58], to
determine whether the addition of multiple image planes
translated into better pre-operative staging performances
(Table 6). Overall, CT scanners using MPR images had
significantly better T staging performances compared toT
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Table 5 Comparison of performance characteristics by imaging technique
AUS CT MRI PET
T staging
j 0.54 ± 0.13 0.55 ± 0.04 0.73 – 0.06a –
Overall accuracy (%) 67.8 ± 10.8 71.5 ± 2.7 82.9 – 3.7a –
T1 accuracy (%) 45.4 ± 10.4 63.0 ± 5.2 86.3 – 5.3a,b –
T2 accuracy (%) 84.4 ± 7.3 72.9 ± 3.6 76.7 ± 6.3 –
T3 accuracy (%) 73.9 ± 15.4 75.3 ± 2.6 86.8 – 3.3a –
T4 accuracy (%) 52.7 ± 31.2 74.9 ± 3.9 80.2 ± 12.8 –
N staging
Overall accuracy (%) 68.1 ± 5.8 66.1 ± 2.1 53.4 ± 5.9 60.0 ± 10.8
Sensitivity (%) 63.0 ± 16.5 77.2 – 2.6c 85.3 – 4.7#,d 40.3 ± 10.9
Specificity (%) 78.8 ± 13.9 78.3 ± 2.5 75.0 ± 9.3# 97.7 – 1.3e
M staging
Overall accuracy (%) 64.7 ± 21.0 81.2 ± 3.4 – 88.2 ± 5.8
Data presented as pooled means ± standard error of all studies within a given category using the inverse variance method. Studies that did not
report raw data for re-calculation were excluded from the pooling analysis. Pooled T and M staging performance characteristics were not
available for PET and MRI, respectively. Bonferroni correction: P B 0.025 (2 comparisons) and P B 0.016 (3 comparisons). Pooled detection
rate for PET was 80.4 ± 4.9%. Values in bold indicate significant differences
# Only one study reported values (i.e., not pooled value)
a MRI significantly higher (P B 0.014) versus CT
b MRI significantly higher (P B 0.0004) versus AUS
c CT significantly higher (P B 0.001) versus PET
d MRI significantly higher (P B 0.0001) versus PET
e PET significantly higher versus CT (P \ 0.0001) and MRI (P = 0.016)
Table 6 Comparison of computed tomography performance characteristics by detector number and MPR images
\4 detectors C4 detectors Axial images MPR images
T staging
j 0.45 ± 0.05 0.65 – 0.03a 0.46 ± 0.04 0.67 – 0.04c
Overall accuracy (%) 62.8 ± 3.6 80.4 – 2.7a 65.2 ± 3.3 81.9 – 3.1c
T1 accuracy (%) 47.5 ± 11.8 75.2 – 5.2a 52.9 ± 9.9 76.4 – 5.7c
T2 accuracy (%) 65.9 ± 5.5 80.0 ± 5.0b 70.4 ± 4.8 77.7 ± 6.3
T3 accuracy (%) 69.3 ± 3.8 84.5 – 2.4a 71.6 ± 3.4 85.3 – 2.7c
T4 accuracy (%) 71.8 ± 6.1 78.8 ± 6.2 69.1 ± 6.5 83.5 ± 5.0d
N staging
Overall accuracy (%) 62.1 ± 3.5 67.1 ± 2.6 63.2 ± 3.0 70.5 ± 2.6d
Sensitivity (%) 79.1 ± 4.2 75.8 ± 3.4 77.1 ± 3.7 77.0 ± 4.1
Specificity (%) 76.4 ± 5.6 78.8 ± 2.9 75.9 ± 4.4 80.1 ± 3.3
M staging
Overall accuracy (%) 79.4 ± 7.5 82.2 ± 7.3 78.6 ± 6.5 83.2 ± 6.6
Data presented as pooled means ± standard error of all studies within a given category using the inverse variance method. Studies that did not
report raw data for re-calculation and studies that did not specify slice number or axial and MPR (multi-planar reformatted) image type were
excluded from the pooling analyses. Values in bold indicate significant differences
a C4 Slices significantly higher (P B 0.03) versus \4 slices
b Trend with C 4 slices higher (P = 0.056) versus \4 slices
c MPR images significantly higher (P B 0.04) versus axial images
d Trend with MPR images higher versus axial images for T4 (P = 0.079) and N staging overall accuracy (P = 0.068)
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axial images. However, additional MPR images did not
significantly affect N or M staging performances.
Discussion
Accurate assessment of pre-operative TNM staging in
gastric cancer is crucial for determining appropriate treat-
ment strategies, especially for planning surgery, which
remains the foundation for cure [1–4]. We reviewed a total
of 40 studies (3758 patients): 3 AUS studies (168 patients)
[37, 42, 43], 32 CT studies (2909 patients) [23–35, 37–42,
44–49, 52–59], 3 MRI studies (109 patients) [36, 49, 51],
and 9 PET studies (422 patients) [29, 44, 45, 50, 55, 56,
60–62] on their pre-operative TNM staging performance
values over the past decade (Tables 1–4/Appendices 1–4 of
the electronic supplementary material).
TNM staging classifications
This review includes studies published over a span of
10 years and as such many TNM staging classifications are
utilized (Appendix B of the electronic supplementary
material). There are no differences between the 3rd and 4th
editions of the UICC/AJCC system, which were incorpo-
rated by 25% of the included studies. Although the 6th edi-
tion divides T2 into T2a and T2b, the studies included in this
review did not incorporate this breakdown; for the purposes
of this review, the 5th and 6th editions are considered the
same (37.5% of the included studies) [18]. The main dif-
ference between the 3rd/4th and 5th/6th UICC/AJCC edi-
tions is the classification of N stage. The 3rd/4th editions did
not have an N3 stage, and the N1 and N2 stages were defined
according to the distance of the perigastric regional lymph
nodes from the edge of the primary tumor [18]. The 5th/6th
editions defined N1, N2, and N3 stages according to the total
number of lymph node metastases present. Additionally, the
5th/6th editions considered metastases to the hepatoduode-
nal nodes as regional lymph nodes, whereas the 3rd/4th
editions considered them as distant metastases (M1 disease)
[18]. The 2nd English edition of the JGCA classification
system was utilized in 30% of the studies [19]. The main
differences between the JGCA and UICC/AJCC systems are
the classifications for N and M stage. The JGCA defines N1,
N2, and N3 stages according to the lymph node groups with
respect to the location of the primary tumor [19]. In general,
Group 1 nodes refer to the perigastric nodes, Group 2 nodes
refer to the nodes along the celiac artery and its branches, and
Group 3 nodes refer to the retropancreatic or paraaortic
nodes, whereas in the UICC/AJCC classification, retropan-
creatic and paraaortic nodes are classified as distant metas-
tases (M1 disease). Furthermore, the 2nd English edition of
the JGCA system does not consider peritoneal, liver, and
cytological metastases as M1 disease (although the presence
of these indicates stage IV disease), whereas the UICC/
AJCC system does [18, 19]. Finally, 7.5% of the included
studies used other staging classifications, such as those
adopted by the World Health Organization (WHO), as well
as those created by the former JGCA (the Japanese Research
Society for Gastric Cancer; JRSGC) in 1993 and 1995.
Despite the incorporation of various classification sys-
tems, this is not a limitation in our meta-analysis. The T
stage breakdown across all editions is the same, because
the T2a and T2b definitions were not incorporated; thus,
the pooling of data and comparison between studies was
not affected. Due to the various N stage classifications, our
meta-analysis only compared the ability to identify N0
versus N? disease, as these definitions are consistent
across all systems, thus making it possible to compare
studies. With respect to M stage, our meta-analysis utilized
the UICC/AJCC and not the JGCA definitions, and thus
considered peritoneal, liver, and cytological metastases as
M1 disease. Re-classification as M1 was possible for the
included studies utilizing the JGCA definitions because the
presence of peritoneal, liver, and cytological metastases
was mentioned within the publications.
Evaluation of T staging
The value of AUS in pre-operative T staging remains
unclear. We did not find any significant differences
between AUS and the other imaging modalities, except for
poor T1 staging performance compared to MRI (Table 5).
The lack of significance is most likely attributable to the
large standard error and limited published studies. We
included only 2 studies that reported pre-operative T
staging values (Appendix 1 of the electronic supplementary
material), one of which had fair agreement (j, 95% con-
fidence interval [CI]: 0.40, 0.20–0.60) and another with
substantial agreement (0.66, 0.55–0.77). This variation
may be explained by the difficulty in staging tumors found
in the gastric fundus and greater curvature [7, 8, 42, 43], as
well as the highly subjective nature of AUS staging and
thus its strong operator dependence [42, 43].
The T staging performance characteristics of CT scan-
ners are moderate, with a pooled j of 0.55, an overall
accuracy of 71.5%, and stage-specific accuracies ranging
from 63 to 75% (Table 5). However, when taking detector
number and MPR images into consideration, the perfor-
mance value of CT is improved (Table 6). Specifically, the
use of C4 detector scanners results in a substantial increase
in agreement with pathology (j = 0.65), an overall accu-
racy of 80%, and stage-specific accuracies ranging from 75
to 84.5%. These results are supported by other studies that
have shown similar improvements in T staging with
increased detector number [10, 11, 13, 63]. Therefore, we
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recommend that pre-operative T staging of gastric cancer
be performed on MDCT scanners with C4 detectors. If
determination of organ invasion is necessary, a higher-
capacity scanner may give more accurate results (T1: 75.2
vs. 47.5% and T3: 84.5 vs. 69.3% for C4 detector and \4
detector scans, respectively, Table 6). Accurate staging of
T1 versus T2 is important for endoscopists considering
endoscopic mucosal resection (EMR) and may be aided by
using EUS [64, 65], whereas accurate staging of T3 versus
T4 is important as the surgeon would need to plan a multi-
visceral resection. The use of MPR images significantly
improved T staging performance compared to axial images
alone, resulting in a substantial agreement with pathology
(j = 0.67), an overall accuracy of 82%, and stage-specific
accuracies ranging from 76 to 85% (Table 6). These results
are supported by other studies that have shown similar
improvements in T staging with multiple image planes [10,
11, 13, 63]. Therefore, we recommend that MPR images be
included in the protocol for pre-operative T staging of
gastric cancer if determination of T stage is critical.
Our results show that MRI had the best overall perfor-
mance characteristics for T staging compared to other
staging modalities, with a substantial agreement with
pathology (j = 0.73), an overall accuracy of 83%, and a
stage-specific accuracy ranging from 77 to 87% (Table 5).
However, it is important to note that only 3 MRI studies
examining 109 patients were included in this review.
Therefore, while the pre-operative T staging ability of MRI
is highly accurate, a publication bias may be present, as all
3 studies reported excellent results (compared to the liter-
ature found on CT scans which included publication of
poor results), which may have caused an overestimation of
its performance abilities. Furthermore, current MRI pro-
tocols are breath-hold-dependent [12, 13, 36, 49, 51]; as
such, it is possible that the patient cohorts included in these
studies were better able to comply than the gastric cancer
population as a whole.
Despite the inability to stage gastric cancer by tumor
depth, PET has a pooled primary tumor detection rate of
80%, which suggests a good overall ability for identifying a
gastric cancer if one exists. Not surprisingly, PET has a
higher capacity to detect advanced gastric tumors
(83–100%) compared to early gastric tumors (26–63%; see
Appendix 4 of the electronic supplementary material).
However, the ability of PET to detect various pathological
tumors varies greatly with type: intestinal type (65.5–83%),
non-intestinal type (41–79%), poorly differentiated ade-
nocarcinomas (61.5–79%), and signet ring cell carcinoma
(0–78%; see Appendix 4 of the electronic supplementary
material).
It is important to mention that the overall accuracy of T
staging for a given study (and for the pooled population) is
dependent on the distribution of T stage within the
evaluated patient population. Typically, T1 and T2 accu-
racies are generally lower than those for T3 and T4 because
of the inability to discriminate depths of invasion in early
cancers. The relationship between T1 versus T2 tumors and
T3 versus T4 tumors, however, is more complicated and
sensitive to operator performance and imaging modality. In
our meta-analysis, a significant difference between
T-staged groups was not found (data not shown). None-
theless, with the exception of MRI, a visible trend was
found for higher T3 compared to T1 accuracies across
modalities (Table 5). However, exceptions to this trend
have been documented. For example, Table 2 shows that
Ahn et al. [23] had a high overall accuracy of 86.4%, with
88% of the patients staged as T1, while Blackshaw et al.
[25] had a low overall accuracy of 60%, with 85% of the
patients staged as T3/T4. Consistent with the concept of
being able to differentiate early versus advanced tumors,
the distribution of the patient population can also have an
effect on the sensitivity and specificity of identifying
lymph nodes. In a patient population with a greater number
of advanced tumors, it is likely that there will be a higher
sensitivity and specificity for identifying lymph node
involvement compared to a population with a greater
number of early tumors, due to a higher pre-test probability
of nodal involvement.
Evaluation of N staging
The ability to stage lymph node (LN) status pre-operatively
in gastric cancer patients remains poor. Our results show
that imaging modalities range in overall accuracy from
53% (MRI) to 66% (CT), in sensitivity from 40% (PET) to
85% (MRI), and in specificity from 75% (MRI) to 98%
(PET), with no significant differences between modalities
(Table 5). The specificities for all modalities were higher
than their respective sensitivities. Among CT scanners,
neither detector number nor MPR images significantly
improved N staging (Table 6). The 85% sensitivity repor-
ted for MRI is from only one study, and thus it cannot be
stated that MRI is clearly superior to other modalities. PET
had the worst sensitivity (40%) of differentiating N0 and
N? nodes, but the best specificity (98%), suggesting it may
be used to clarify true positive patients. These results
confirm the analysis of another review that showed neither
AUS, MDCT, conventional MRI, nor PET could reliably
confirm or exclude the presence of LN metastasis [66].
Tumor-positive LNs are not always enlarged, and certain
enlarged LNs are not always tumor-positive but instead are
enlarged due to inflammation, both of these possibilities
make N staging extremely difficult [15, 66]. Moreover,
there are varying LN size criteria (ranging from [6 mm to
[1 cm) required for LN detection [10]. We found that the
majority (68%) of the studies incorporated a definition of
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C8 mm for LN involvement, although this criterion was
applied to the short axis diameter in some cases and the
long axis diameter in other cases (Appendix 2.4 of the
electronic supplementary material). These size-dependent
diagnostic criteria for AUS, CT, and MRI may also con-
tribute to the lower specificity found among these modal-
ities compared to PET, which utilizes a metabolic
diagnostic criterion. However, the mean SUV noted for N
staging can also vary, with overall values ranging from 4.5
to 6.8 (Table 4), and mean SUVs overlapping between N
stage categories (N0: 3.5–6.0; N1: 2.7–7.5; N2: 4.5–9.0;
N3: 6.2–8.7; Appendix 4.4 of the electronic supplementary
material). These inaccuracies in true nodal status make pre-
operative determination of disease spread difficult, and
must be taken into account in reports of pre-operative
staging for neoadjuvant and peri-operative treatments, as
well as in the selection of patients for EMR in early gastric
cancer. However, the progress made in the field of
molecular biology, where studies have successfully docu-
mented the ability to use specific radio-labeled probes to
tag and identify specific tumor antigens and/or receptors
[67], will undoubtedly contribute to the advancement of
pre-operative staging in gastric cancer, which should lead
to more effective staging strategies in the future.
Evaluation of M staging
Currently, pre-operative M staging of gastric cancer can be
best assessed by PET and C4 detector CT (overall accu-
racies of 88 and 82%, respectively; Tables 5 and 6).
However, only 3 PET studies, compared to 11 CT studies,
reported M staging accuracies. The value of AUS in M
staging remains unclear. It had a pooled overall accuracy of
65%, but only 2 studies evaluated its potential (Table 1),
resulting in high variation. The value of MRI in M staging
was not assessed in any studies evaluated. In practice, MRI
is not suitable for screening for metastases because of the
limited area of the body that can be scanned in a single
session [14]. However, it is often used to characterize non-
specific liver lesions found by CT [68]. A limitation of this
review is that pre-operative staging studies were included
only if patients had a post-operative pathology report for
comparison. Patients who were not offered curative
resection on the basis of metastases found on pre-operative
imaging were excluded. Therefore, the false-positive rate
for metastatic disease may indeed be higher for all imaging
techniques.
Overall
Despite the reasonable T and M staging abilities of CT, MRI,
and PET, all are far from perfect. The importance of accurate
pre-operative TNM staging has been demonstrated by
studies that show pre-operative staging frequently differs
from post-operative assessments. Schwarz [5] found that
post-operative assessment (based on intra-operative findings
and pathology) differed from pre-operative staging in 29% of
patients. In 45% of the cases, the changes in curative intent
could be traced to uncertainty of diagnosis or disease extent
[5]. Furthermore, 45.5% of patients with pre-operative stage
assignment were ultimately re-classified into a different
pathologic stage category post-operatively, and patients
undergoing a curative-intent procedure were re-staged
50.4% of the time intra-operatively [5]. These high re-stag-
ing rates support the use of diagnostic laparoscopy (DL) to
clarify pre-operative intent. Our review on the use of DL in
gastric cancer found that DL changed management in
10–60% of cases [69].
It may be possible to increase the accuracy of pre-
operative assessments by using combined staging modali-
ties. van Vliet et al. found that the performance of CT alone
was not sensitive enough for the detection of distant
metastases, whereas the performance of AUS, neck US,
and chest X-ray, in combination with CT resulted in higher
accuracies in patients with esophageal or gastric cardia
cancer [70]. Chen et al. [29] reported that the combined use
of PET and CT was more accurate for pre-operative N and
M staging that either modality alone; however, the com-
bined pre-operative staging accuracy was still low, 66%.
Therefore, further research is required to determine whe-
ther pre-operative TNM staging is improved by using
combined and/or multiple imaging techniques.
Finally, the performance characteristics of a staging
modality are determined by both the experience of the
investigator and the quality of protocols, as well as by the
equipment. Blackshaw et al. [63] found that pre-operative
TNM staging by CT improved significantly with radiolo-
gist experience, with lower agreements in the first 75
patients compared to the last 25 patients staged. In this
examination of the learning curve, the authors reported a
twofold improvement in tumor detection and a sevenfold
improvement in suspicious LN detection [63]. Variations in
CT scanning protocols and equipment have been reported
by Callaway and Bailey [71]. These authors surveyed 5
cancer networks (21 hospitals) covered by the South West
Cancer Intelligence Service of the United Kingdom [71].
They found variation in the following: MDCT capabilities,
gastric cancer patient volume, number of radiologists in
each institution, radiologist specialty, CT scanning proto-
col, and image type used to evaluate patients [71]. Varia-
tions in scanning protocols included the use of various
positive (gastrograffin vs. barium) and negative (water vs.
milk) oral contrasts, execution of a pre-contrast scan,
timing of scans (arterial phase vs. portal phase vs. both),
and scan location (chest vs. abdomen vs. pelvis) [71].
Given these results, it is clear that pre-operative TNM
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staging studies contain heterogeneous data, which may
explain the high variation in performance characteristics
reported by the studies included in our review. Importantly,
the results reported in journal articles are likely better than
those achieved on average. The publication of current and
clear guidelines/protocols for routinely used imaging
techniques is advocated.
Conclusion
The agreement between pre-operative TNM staging by
radiology imaging and post-operative staging by pathology
is far from perfect. For pre-operative T staging the per-
formance characteristics of AUS and CT were not signifi-
cantly different; however, MRI had a better performance,
although in a limited number of patients. Among CT
scanners, those using C4 detectors and MPR images per-
formed better than scanners with \4 detectors and axial
images only. For pre- operative N staging overall accuracy
was not significantly different across modalities; however,
PET had the worst sensitivity yet highest specificity among
modalities. CT performance did not significantly differ by
detector number or addition of MPR images. For pre-
operative M staging performance did not significantly
differ by modality, detector number, or addition of MPR
images. However, the lack of significance was most likely
due to large standard errors. Operator dependence and
heterogeneity of data may account for the variations in
staging performance. Physicians should consider the
implications of staging inaccuracy, and may want to use
multiple imaging modalities and/or DL to confirm the
specifics of a tumor prior to developing treatment strategies
for gastric cancer patients.
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